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ABSTRACT 
 Multiple sclerosis (MS), neuromyelitis optica (NMO), and transverse 
myelitis (TM) are devastating autoimmune neuroinflammatory disorders that 
produce varying levels of disability. The presence of psychological symptoms 
including depression, fatigue, and pain has been long documented and 
researched in MS patients. Only recently have few studies begun to estimate the 
prevalence of depression, fatigue, and pain in NMO patients, and no existing 
literature focuses on the psychological burden of TM. Our research question 
focused on the prevalence of these psychological issues in NMO, TM, and MS 
patients, and how disability relates to depression, fatigue, and pain in these 
disease groups. We developed a research study using a survey format where 
NMO, TM, and MS participants completed a series of online surveys assessing 
disability, depression, fatigue, and pain. We used the patient-administered 
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Expanded Disability Status Scale (EDSS) to assess disability, the Beck 
Depression Inventory (BDI) to assess depression, the Fatigue Severity Scale 
(FSS) to assess fatigue, and the short form Brief Pain Inventory (BPI) to assess 
pain. In all, 15 NMO, 14 TM, and 23 MS patients participated in the study. While 
we did not find a significant difference between disease groups on any outcome 
measure in this limited sample size, we did observe several trends. First, NMO 
and TM patients had higher levels of disability and pain severity than MS 
patients, yet MS and TM patients displayed more fatigue and depressive 
symptomatology than NMO patients. Relationships between disability scores and 
the psychological outcome variables (BDI, FSS, and BPI scores) were assessed 
by correlational analysis. We found that disability correlated with measures of 
depression (r = +0.56), fatigue (r = +0.42), pain severity (r = +0.50) and pain 
interference (r = +0.42) in the MS group.  
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INTRODUCTION 
 Multiple sclerosis (MS), neuromyelitis optica (NMO), and idiopathic 
transverse myelitis (TM) are the most common autoimmune inflammatory 
disorders that target the central nervous system (CNS). These disorders may 
cause motor, visual, and cognitive impairments, temporary or permanent 
disability, and in some cases death. Multiple sclerosis is the most prevalent 
neuroinflammatory disorder, and within the last decade significant research 
efforts have been made to analyze the psychological burden of this neurological 
disease. Scientific research has also begun to analyze depression, pain, and 
other psychological factors in NMO patients, but to our knowledge the 
psychological burden of idiopathic TM has not yet been analyzed. Because of the 
similarities in symptomatology between MS and other neurological disorders, we 
aimed to analyze the impact these diseases have on the psychological wellbeing 
of patients. 
BACKGROUND INFORMATION ON DISORDERS 
Each of these autoimmune inflammatory disorders can be characterized 
by episodes of transverse myelitis (TM). An episode of transverse myelitis can 
occur secondary to demyelinating conditions such as MS or NMO, other systemic 
inflammatory disorders such as systemic lupus erythematosis (SLE), or as a 
result of tissue damage following infection (Awad & Stüve, 2011; Jacob & 
Weinshenker, 2008). In addition, a considerable portion of TM events can be 
classified as idiopathic, or having no known origin (Awad & Stüve, 2011). 
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Although each disorder can include episodes of transverse myelitis, it is 
important to understand the characteristics and pathogenesis of each disease as 
treatment and prognosis can vary greatly. For example, the use of interferon 
beta, a common therapy for MS, in an NMO patient may exacerbate their 
disorder (Mealy MA, 2012). This is particularly noteworthy as misdiagnosis is 
common among these disorders with common symptomologies. For example, 
one study found that 29.4% of NMO patients had received a previous 
misdiagnosis of multiple sclerosis (Mealy MA, 2012).  
These diseases are inherently different from one another in their 
diagnostic criteria, clinical course, high-risk populations, and pathogenesis 
(Lassmann, Brück, & Lucchinetti, 2007). It is our goal to not only assess the 
biological differences between these three autoimmune disorders, but to take into 
account the burden of each disease on a patient’s psychological mindset and 
quality of life. We must understand the background information on MS, NMO, 
and idiopathic TM in hopes of being able compare the psychological burden of 
each disorder and to relate biological disease processes to changes in 
psychological well-being. 
Multiple Sclerosis 
Our discussion will begin with multiple sclerosis, the prototype 
autoimmune inflammatory disorder of the central nervous system. MS occurs 
when an inflammatory immune response results in injury to axons and glia, 
causing neurological dysfunction and neurodegeneration. The McDonald Criteria, 
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developed in 2001, integrates magnetic resonance imaging (MRI) assessment 
with clinical and paraclinical methods to formulate a list of diagnostic criteria for 
MS (McDonald et al., 2001). The original McDonald criteria mandated that two or 
more attacks, or neurological disturbances caused by inflammatory or 
demyelinating lesions, must occur in a patient to be considered for an MS 
diagnosis. A set of Revised Criteria, developed by Polman et al. (2005), 
elaborate on the McDonald criteria by requiring evidence that the lesions are 
disseminated in time and space. The Revised Criteria also clarify that spinal cord 
lesions must be focal to be considered in a diagnosis of MS (Polman et al., 
2005). While traditional MS diagnostic criteria emphasized the disease’s impact 
on white matter, current research demonstrates a more diverse spectrum of 
lesions, both in form and location. MS brain lesions are often focal, but they can 
occasionally be diffuse in nature. Histopathological and MRI data suggest the 
disease can also target the cortical gray matter, especially during the late stages 
of MS (Lassmann et al., 2007; Ontaneda, Hyland, & Cohen, 2012). Spinal cord 
lesions in MS patients normally extend less than 2 vertebral lengths and produce 
asymmetric/unilateral symptoms (Jacob & Weinshenker, 2008). 
The effects of demyelination are apparent in the symptomatology of 
multiple sclerosis. Symptoms include cognitive impairment, visual deficits, 
tremors, difficulties with balance, vertigo, weakness, spasticity, and/or poor 
swallowing and speech (Compston & Coles, 2002). Optic neuritis is the most 
common symptom of MS, as well as many patients’ initial symptom (Nakajima et 
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al., 2010). Eighty percent of patients present with the relapsing-remitting form of 
MS, while 20% present with a progressive form of the disease. The relapsing-
remitting form is characterized by periods of neurological dysfunction (relapses) 
interspersed with relative stability of symptoms. Over time, relapsing-remitting 
multiple sclerosis (RRMS) evolves to a form with continual worsening of 
symptoms, secondary progressive multiple sclerosis (SPMS) (Compston & 
Coles, 2002; Moore et al., 2012). Because the mechanisms of tissue injury in MS 
are heterogeneous, the form and stage of the disease, as well as individual 
differences between patients, must be analyzed to implement appropriate 
therapies (Lassmann et al., 2007). 
 Approximately 400,000 individuals in the United States suffer from MS 
(Zwibel & Smrtka, 2011). Multiple sclerosis is a much more prevalent disease 
than neuromyelitis optica or transverse myelitis, with the lifetime risk approaching 
1 in 400 (Compston & Coles, 2002). MS affects women twice as frequently as 
men (Compston & Coles, 2002). This is in accordance with the gender pattern 
seen in most autoimmune disorders. MS is fairly common in the U.S., Canada, 
Europe, Australia, and New Zealand (Ascherio & Munger, 2008), suggesting this 
neuroinflammatory disease is more prevalent in individuals of northern European 
descent (Ontaneda et al., 2012). The lifetime risk for high-risk populations (i.e. 
Caucasian women) approaches 1 in 200 (Ascherio & Munger, 2008). MS is the 
most common chronic neurological disorder in young people that does not arise 
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from trauma. The age of onset generally falls between 20 and 50 years (Zwibel & 
Smrtka, 2011).  
The pathogenesis of multiple sclerosis is marked by demyelination of 
axons. Although the cause of multiple sclerosis is still unknown, various 
autoimmune and viral theories have been proposed. Myelin increases the 
velocity of nerve impulses via saltatory conduction, and destruction of myelin 
produces many of the neurological deficits present in MS patients. Active 
demyelination and degeneration take place in the context of inflammation 
(Lassmann & van Horssen, 2011). The traditional view of MS pathogenesis 
encompasses a T-cell mediated destruction of the axonal myelin sheath, 
although a humoral immune response has also been implicated in MS 
pathogenesis (Brück et al., 2012). These immune responses form focal 
demyelinated plaques primarily in the white matter of the CNS (Lassmann et al., 
2007). Current research demonstrates the vast heterogeneity in pathological 
patterns of MS, with demyelination being associated with T-cells, macrophages, 
immunoglobulin and complement deposition, and/or apoptotic oligodendrocytes 
(Brück et al., 2012).  
In addition, there is a strong suggestion that genetics and the environment 
play a role in susceptibility to MS (Lassmann & van Horssen, 2011). The major 
histocompatibility complex (MHC) on chromosome 6 has the strongest 
association for a predisposition to MS (Ontaneda et al., 2012) and the human 
leukocyte antigen-DRB1 (HLA-DRB1) locus has been linked to MS risk (Ascherio 
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& Munger, 2008). Siblings of MS patients have a 30-fold increased risk of MS 
compared to the general population (Ascherio & Munger, 2008), demonstrating 
the influence of genetics on susceptibility. Recently, research has focused on the 
role of Epstein-Barr virus (EBV) on the risk for developing MS, with a higher titer 
of EBV specific antibodies translating to higher risk (Ascherio & Munger, 2008; 
Lucas et al., 2011; Ontaneda et al., 2012). Environmental factors such as latitude 
and cigarette smoking have also been suggested as having an impact on the risk 
of developing MS. Specifically, Vitamin D and ultraviolet (UV) radiation from 
sunlight may serve a protective role, with these factors being greater at 
equatorial latitudes (Ascherio & Munger, 2008). Studies focusing on changing 
risks of MS in migrant populations have suggested that risk of incidence falls 
somewhere between the birthplace and final residence of the individual (Ascherio 
& Munger, 2008). Cigarette smoking, on the other hand, seems to increase the 
likelihood of developing in MS, with a 70% increased MS risk in heavy smokers 
(Ascherio & Munger, 2008). 
Neuromyelitis Optica 
Neuromyelitis optica, also known as Devic’s disease, is a rare 
neuroinflammatory disorder that primarily targets the spinal cord and optic nerve, 
resulting in episodes of transverse myelitis and optic neuritis. In this disorder, the 
transverse myelitis events are often longitudinally extensive, and the optic 
neuritis events are typically bilateral (Oh & Levy, 2012). Optic neuritis events in 
NMO patients are typically more severe than in MS (Thornton, Rizzo, & Cestari, 
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2011). The Wingerchuk 2006 diagnostic criteria are used for a clinical diagnosis 
of NMO. For a definitive case of NMO, a patient must exhibit (D. M. Wingerchuk, 
Lennon, Pittock, Lucchinetti, & Weinshenker, 2006): 
• Optic neuritis 
• Acute myelitis 
• At least two of three supportive criteria 
1) Contiguous spinal cord MRI lesion extending over >3 
vertebral segments 
2) Brain MRI not meeting diagnostic criteria for multiple 
sclerosis 
3) Neuromyelitis optica-immunoglobulin G (NMO-IgG) 
seropositive status   
In contrast to MS, brain lesions are uncommon in NMO patients early in the 
disease, although sometimes observed (Graber, Levy, Kerr, & Wade, 2008). An 
abnormal brain MRI may contribute to an NMO patient’s initial misdiagnosis with 
MS (Mealy MA, 2012). In the past, NMO was considered a variant type of MS, 
although it is now considered an entirely separate disorder with different 
diagnostic criteria, immunopathogenesis, and therapeutic treatments (Thornton 
et al., 2011).  
As in MS, the initial event in NMO is typically optic neuritis (Mealy MA, 
2012). The disease course is almost always recurrent, with the relapse rate 
around 1.3 events/year (Mealy MA, 2012), signifying the need for early diagnosis 
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and treatment. Common symptoms of an NMO optic neuritis attack are loss of 
visual acuity and pain with eye movement, while an acute transverse myelitis 
attack in NMO is commonly characterized by paraplegia, spasticity, Lhermitte’s 
phenomenon, and bladder dysfunction (Oh & Levy, 2012). Whereas TM events in 
MS produce asymmetric symptoms, NMO patients experience changes in 
sensation and other symptoms symmetrically (Oh & Levy, 2012). 
NMO is more prevalent in non-Caucasian populations, and especially in 
African and Asian racial groups (Jacob & Weinshenker, 2008; Thornton et al., 
2011). While nations with a mostly white population observe NMO cases in less 
than 2% of all demyelinating disorders, the prevalence of NMO cases in 
predominantly non-white nations approaches 10-40% of CNS demyelinating 
disorders (Oh & Levy, 2012). One U.S. study found that while their NMO patient 
population was almost half Caucasian, patients of African descent were vastly 
overrepresented in the sample group as compared to the general U.S. population  
(Mealy MA, 2012).  The gender distribution in NMO shows a female to male ratio 
of 6.5:1 (Mealy MA, 2012), which is greater than that in MS. NMO patients are 
also typically older at 41 years when they present with the disease compared to 
MS patients who present in their late 20s (Mealy MA, 2012). 
The discovery of an NMO disease-specific antibody in 2004 (Lennon et 
al., 2004) has improved patient screening and assisted in the understanding of 
this disorder’s clinical, immunological, and pathological profile (Oh & Levy, 2012; 
Thornton et al., 2011). The antibody, known as NMO-IgG, targets aquaporin-4 
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(AQP4), a transmembrane protein that serves as a channel that regulates water 
entry into and out of astrocytes in the CNS (Ratelade & Verkman, 2012). The 
interaction of astrocytes with endothelial cells helps to maintain the blood-brain 
barrier (BBB) (Graber et al., 2008). NMO patients often have antibodies to AQP4, 
and pathogenesis occurs when these immunoglobulin G (IgG) antibodies attach 
to the AQP4 receptors and the complex becomes internalized (Graber et al., 
2008). AQP4-specific B cells and T cells are also implicated in the NMO 
autoimmune response (Graber et al., 2008). NMO-IgG binding to AQP4 on 
astrocytes may also cause complement cytotoxicity and eventual blood-brain 
barrier breakdown, destruction of oligodendrocytes, demyelination, and neuronal 
loss (Ratelade & Verkman, 2012). The discovery of the NMO-IgG antibody was a 
landmark finding as it serves as the first serum marker capable of differentiating 
NMO from MS and other diseases (Lennon et al., 2004). Screening tests for 
NMO-IgG were validated and are highly specific (91-100%) and varyingly 
sensitive (57-91%) (Oh & Levy, 2012). This screening tool helps identify NMO 
patients quickly and efficiently, and decreases the likelihood of an NMO patient 
being misdiagnosed with MS. 
Idiopathic Transverse Myelitis 
Transverse myelitis is an inflammatory reaction in the spinal cord capable 
of producing lesions that are focal (less than three vertebral segments) or 
longitudinally extensive (greater than three vertebral segments). As discussed 
previously, a TM event can be secondary to a demyelinating, inflammatory, 
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infectious, or other specified event. Acute myelitis events are most commonly 
classified as idiopathic, or having an unknown origin (Jacob & Weinshenker, 
2008). However, the number of idiopathic TM events is shrinking with the 
discovery and development of sensitive and specific disease markers and 
diagnostic tools (Awad & Stüve, 2011). A diagnosis of idiopathic TM is a 
diagnosis of exclusion, when all other possibilities have been ruled out. For our 
study purposes, we will only analyze patients who had a monophasic idiopathic 
TM event in retrospect, as recurrent TM events suggest an underlying disorder. 
When a patient presents with myelopathy, the initial steps in determining whether 
the myelopathy is a TM event are exclusion of a compressive cause and MRI 
evidence of an intrinsic spinal cord lesion (Jacob & Weinshenker, 2008). Since all 
demyelinating, neoplastic, infectious, and inflammatory causes are ruled out in a 
diagnosis of idiopathic TM, a list of exclusion criteria must be met. History of 
radiation to the spine, compressive disc disease, vascular disorders (i.e. 
vasculitis, arteriovenous fistula), connective tissue disease, and certain infections 
preclude a diagnosis of idiopathic TM. In addition, a brain MRI attributable to MS, 
and a history of optic neuritis consistent with NMO exclude idiopathic TM as a 
diagnosis (Jacob & Weinshenker, 2008). Common inclusion criteria for idiopathic 
TM are as follows (Jacob & Weinshenker, 2008): 
• Sensory, motor, or autonomic  dysfunction attributable to the spinal 
cord 
• Bilateral signs and/or symptoms 
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• A clearly defined sensory level 
• Inflammation demonstrated by lab or MRI findings 
• Progression to nadir between 4 hours and 21 days after onset  
Transverse myelitis can be detected via abnormal cord signal on an MRI, 
and lesions may be enhancing or nonenhancing. The abnormal signal is often 
uniform and central in idiopathic TM. Transverse myelitis lesions may often 
diminish over time (Sepúlveda et al., 2012), making the diagnosis of a remote TM 
event difficult. Oftentimes, patients with a TM event will present with an 
inflammatory cerebrospinal fluid (CSF) profile, including pleocytosis and 
increased protein levels in the CSF (Awad & Stüve, 2011). The most common 
symptoms of a TM event are back pain, lower limb paresthesias, allodynia, 
paraparesis, and bladder dysfunction (Awad & Stüve, 2011).  
 The annual incidence of idiopathic acute TM in the U.S. is 1.34-4.6 per 
million per year (Awad & Stüve, 2011). Idiopathic TM exhibits two age peaks in 
onset: one between the ages of 10 and 19, and one peak between the ages of 30 
and 39 years (Jacob & Weinshenker, 2008). No study to date has revealed any 
racial, familial, gender, or geographic predilection that increase an individual’s 
susceptibility to having a transverse myelitis event (Awad & Stüve, 2011; West, 
Hess, & Cree, 2012). 
DISABILITY AND PSYCHOLOGICAL FACTORS 
 The background information on each disease paints a portrait of the 
biological mechanisms involved in MS, NMO, and TM pathogenesis, in addition 
  12 
to the physical symptoms patients generally experience. Since all three disorders 
occur in the context of an inflammatory reaction within the central nervous 
system, many symptoms are shared between disorders. We are interested in 
how the psychological burden of each disease impacts a patient’s quality of life, 
as well as how a patient’s level of disability impacts their psychological well-
being. Past research has illustrated the prevalence of fatigue, cognitive function, 
psychiatric symptoms, pain, and physical disability in MS patients (Arnett, 
Barwick, & Beeney, 2008). There has been a vast amount of research in the past 
several decades dedicated to the psychological burden of MS, but only in the 
past several years have studies been published on the psychological well-being 
of NMO patients. To our knowledge, no research to date has analyzed the 
prevalence of depression, fatigue, and pain in idiopathic TM patients. This is 
likely due to the fact that NMO and idiopathic TM are rare diseases.  
 To conduct our study, we chose to focus on disability as well as the 
psychological variables of depression, fatigue, and pain. A description of each of 
these variables and the current literature that exists relating these variables to 
MS, NMO, and idiopathic TM follows. 
Disability 
The Expanded Disability Status Scale (EDSS) was developed in 1983 
(Kurtzke, 1983) and remains the most widely used clinical measure of disability in 
multiple sclerosis (Bowen, Gibbons, Gianas, & Kraft, 2001). The EDSS score is 
determined by a physician in a clinical setting, and this score reflects the amount 
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of deficit attributable to MS. There are 8 Functional Systems (FS) scores used to 
tabulate a composite EDSS score ranging from 0 (normal) to 10 (death due to 
MS). The FS categories consist of Pyramidal, Cerebellar, Brain Stem, Sensory, 
Bowel and Bladder, Visual, Cerebral, and Other (miscellaneous). Each FS is 
scored on a scale of 0 to 5 or 6, with the exception of the Other FS, which is 
scored as a dichotomous outcome of 0 (symptoms absent) or 1 (symptoms 
present) (Kurtzke, 1983).  An EDSS scoring scale that includes descriptions of 
the level of disability expected at each EDSS score is provided in Table 1. 
In addition to the EDSS score at nadir, predictive factors for long-term 
disability in relapsing-remitting MS include MRI findings, severity of initial 
symptoms, relapse profile, and CSF profile (Baumstarck et al., 2013). Recently, a 
self-administered Expanded Disability Status Scale was developed for use in MS 
patients, in hopes of eliminating the need for a skilled practitioner to assign a 
score of disability. The self-administered composite EDSS scores and 
bowel/bladder FS scores correlate well with the practitioner-derived EDSS 
scores, although patients tended to rate themselves as more disabled than 
physicians did (Bowen et al., 2001). 
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Table 1. Kurtzke Expanded Disability Scale. EDSS scores (0-10) 
accompanied by a description of expected disability level (Kurtzke, 1983). 
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MS patients have a wide range of prognoses that mirror the heterogeneity 
of the disease. While 25% of MS patients do not have symptoms which alter their 
daily lives, 15% become disabled within a short period of time (Compston & 
Coles, 2002). One study collected data from an MS patient sample with a mean 
period since diagnosis of 12 years and found that 90% of patients reported 
impairments in mobility (Hemmett, Holmes, Barnes, & Russell, 2004; Zwibel & 
Smrtka, 2011). Normally, more motor dysfunction is associated with a poorer 
prognosis (Compston & Coles, 2002). Studies have also examined relationships 
between disability and other factors. Cognitive impairment at diagnosis was 
found to independently predict EDSS deterioration over 5-7 years (Ruet et al., 
2012). The effect of physical disability on depression is still unclear. About half of 
the studies conducted on this topic found no relationship, while the other half 
reported a positive association between physical disability and depression (Arnett 
et al., 2008) Greater disability is also associated with unemployment and 
lessened productivity at work (Glanz et al., 2012), and 92% of MS patients are 
unemployed after 30 years (Zwibel & Smrtka, 2011). 
NMO tends to be more severe and have a poorer prognosis than MS (D. 
M. Wingerchuk et al., 2006; Dean M. Wingerchuk, Hogancamp, O’Brien, & 
Weinshenker, 1999). Before preventive therapy was widely used in NMO, 50% of 
NMO patients became fully blind and unable to ambulate independently within 5 
years of disease onset, and 20% died due to respiratory failure (Nakajima et al., 
2010). Bowel and bladder dysfunction is more severe in NMO than in MS, while 
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cognitive function is worse in MS than in NMO (Chanson et al., 2011). In a study 
by Chanson et al. (2011), NMO patients had worse physical health composite 
scores than MS patients. Although physical function is typically worse in NMO 
then MS, NMO patients typically perceive less role limitations due to physical 
disabilities than MS patients (Chanson et al., 2011). Breakdown of the blood-
brain barrier is an important component of pathogenesis in NMO and MS. The 
level of BBB breakdown is associated with disease severity. One study that 
correlated BBB permeability with clinical disability found that BBB permeability is 
higher in patients with NMO than in patients with MS. The severity of 
inflammation (which is greater in NMO) accounts for the increased level of 
disability typically found in NMO patients (Tomizawa et al., 2012).  
A limited number of studies discuss disability in transverse myelitis cases, 
with the consensus that an acute TM event is highly unpredictable and ranging in 
severity (Gajofatto et al., 2010). Prognosis depends on the severity of the TM 
event, and one study found the EDSS score at nadir was the only predictive 
factor associated with a patient’s clinical outcome (Sepúlveda et al., 2012). 
Interestingly, the length of the spinal cord lesion, which determines whether or 
not the lesion is focal or longitudinally extensive, did not seem to be associated 
with clinical outcome (Sepúlveda et al., 2012). In other studies, other factors 
correlated to a poorer prognosis in idiopathic TM including “rapid progression of 
symptoms, back pain, and spinal shock, as well as absent central conduction on 
somatosensory evoked potential testing” (West et al., 2012). 
  17 
Depression 
Depression is a psychiatric mood disorder outlined in the Diagnostic and 
Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). To be diagnosed 
with depression, an individual must present with five or more of the following 
symptoms for at least two weeks: a loss of pleasure or interest in one’s usual 
activities (required for diagnosis), a sad or depressed mood most of the time 
(required for diagnosis), sleeping problems, fatigue, psychomotor retardation or 
agitation, changes in appetite and weight loss, a negative self-image, feelings of 
guilt or self-blame, and/or reduced concentration and suicidal thinking (Siegert & 
Abernethy, 2005). Depression has a proven negative impact on quality of life and 
can reduce productivity in the workplace (Glanz et al., 2012). 
A plethora of research exists documenting the prevalence of depressive 
symptoms in MS patients. The lifetime risk of major depression in healthy 
populations is 10-15%, while the lifetime risk approaches 50% for individuals with 
MS (Arnett et al., 2008; Sarısoy, Terzi, Gümüş, & Pazvantoğlu, 2012; Siegert & 
Abernethy, 2005). The rates of depression in MS samples are also consistently 
higher than groups with other chronic illnesses (Siegert & Abernethy, 2005). In 
RRMS patients, depression scores increase during a relapse and decrease post-
relapse. However, the rates of possible depression remain high even after 
relapses, demonstrating the persistence of depressive symptoms even after 
physical symptoms improve (Moore et al., 2012). One longitudinal study 
examining health-related quality of life in MS patients after initial diagnosis found 
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that physical functioning and overall quality of life deteriorate over time (Ruet et 
al., 2012). A high EDSS score is the strongest predictor of depression (Chanson 
et al., 2011). Depression levels are generally higher with more severe 
neurological impairment and greater disability (Vattakatuchery, Rickards, & 
Cavanna, 2011).  
The largest study on depression in MS was conducted using the web 
portal of the UK MS Register. Using the Internet, researchers collected 
information on depression and anxiety in over 4000 individuals with MS. This 
study found that men and women with secondary progressive MS were more 
depressed than those with other types of MS (Jones et al., 2012). There was little 
or no relationship found between age and depression score, time since first 
symptoms of MS and depression score, or time since MS diagnosis and 
depression score. This study also found that women were more frequently 
anxious than men, while men were more frequently depressed than women. 
However, these results may be confounding, as this sample contained more men 
with primary progressive MS (PPMS) or SPMS, which are associated with 
greater levels of depression than RRMS (Jones et al., 2012). The results also 
found that anxiety and depression were often comorbid, and many individuals 
experience moderate/severe depression in addition to moderate/severe anxiety 
(Jones et al., 2012). This result is in accordance with the relationship between 
depression and anxiety observed in the general population.  
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A particularly troubling issue in the psychological burden of MS is the 
reality that depression in MS patients often goes unrecognized or untreated. This 
can have severe consequences, as 25% of MS patients exhibit suicidal ideation. 
Out of these patients, one-third do not receive psychiatric help and two-thirds are 
not offered antidepressant medication (Zwibel & Smrtka, 2011). A study that 
recorded the causes of death of MS patients not attributable to MS revealed 
28.6% of these deaths were suicides (Siegert & Abernethy, 2005). This illustrates 
the need for effective diagnosis and treatment for MS patients suffering from 
depression. 
 Because much of the disease burden of MS is located in the brain, 
attention has been focused on physical characteristics of the disease and their 
relationships to psychiatric symptoms in MS patients. Although population 
samples in studies may not be representative, there is some evidence that MS 
patients with brain lesions showed higher levels of depression than patients 
whose lesions were confined to the spinal cord (Siegert & Abernethy, 2005). In 
the most comprehensive study on the association of structural brain 
abnormalities and depression in MS patients, Feinstein et al. determined that 
patients with major depression had greater hyperintensity of lesions in the left 
medial inferior prefrontal cortex, as well as greater structural atrophy (more CSF 
volume compared to gray matter volume) in the left anterior temporal region 
(Feinstein et al., 2004).  Some data suggests an association between 
demyelination and depression, and higher levels of immunologic variables (i.e. 
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T4+ helper cell counts, CSF white blood cell counts) have been associated with 
greater depression (Arnett et al., 2008). A higher CD4/CD8 ratio is also 
associated with higher levels of depression (Vattakatuchery et al., 2011). This 
data suggests that while the physical disease of MS may contribute to depressive 
symptoms in patients, these associations are unclear and may be limited. For 
example, MS sequelae include fatigue, cognitive deficits, pain, and physical 
disability, and these symptoms may have a more direct influence on the level of 
depression in MS patients than the biological processes of the disease itself. In 
addition, depression is also moderated by social support, coping skills, stress, 
and how individuals perceive themselves and/or their illness (Arnett et al., 2008). 
The roles of these psychological and psychosocial factors in mediating 
depression illustrate the complexity of the relationships between factors thought 
to contribute to depression. 
 Only recently have studies begun to analyze the prevalence of depression 
in NMO patients. As in MS, the health-related quality of life of NMO patients is 
significantly worse than in healthy populations (Chanson et al., 2011), but results 
differ when comparing MS to NMO groups. When groups of NMO and MS 
patients were compared, the intensity of depression was similar between groups 
(Chanson et al., 2011). In the same study, a mental health composite score using 
health-related quality of life measures suggested a better health composite score 
in NMO versus MS, but another study found higher scores of depression in NMO 
patients (Qian et al., 2012). Immunosuppressive treatment did not have an 
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impact on levels of depression in NMO. In NMO, cognitive function is negatively 
correlated with depression scores during acute relapses (He, Chen, Zhao, & 
Zhou, 2011). One study compared a group of NMO patients to a healthy control 
group in addition to a group of depressed patients.  Beck Depression Inventory 
(BDI) scores for NMO patients were significantly higher than for healthy control 
group (He et al., 2011), but were significantly lower than the sample of depressed 
patients.  
 To our knowledge, no study to date has looked at the prevalence and 
effects of depression in patients with idiopathic transverse myelitis.  
Fatigue 
Fatigue is a subjective term, most often defined as an “overwhelming 
sense of tiredness that is out of proportion to ‘normal’ tiredness” (Induruwa, 
Constantinescu, & Gran, 2012). Because fatigue is a general term that 
encompasses a wide spectrum of severity in symptoms, the definition of fatigue 
remains vague in the medical sense (Kluger, Krupp, & Enoka, 2013). The 
presence of fatigue is nearly universal in MS symptomatology, with 88% of MS 
patients experiencing severe fatigue (Arnett et al., 2008). A medical definition of 
fatigue in MS suggests that fatigue in MS patients “has usually been present for 
years and has greater severity than any premorbid fatigue” (Mills & Young, 
2008).  
Fatigue not only encompasses the physical feeling of tiredness, but also 
includes a mental component. This multidimensional effect of fatigue can have 
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detrimental impacts on cognitive function as well as the physical energy required 
to carry out daily activities, and 28% of MS patients name fatigue as their most 
disabling symptom (Arnett et al., 2008).  Fatigue is a common symptom in MS, 
but is also present in many individuals with depression. Although some earlier 
studies have shown unclear results in the relationship of fatigue to depression 
(Siegert & Abernethy, 2005), more recent research illustrates fatigue as a 
contributing factor to the development of depression (Arnett et al., 2008). The 
relationship between fatigue and depression remains poorly understood, as the 
two disorders may simply be comorbid rather than causative (Łabuz-Roszak, 
Kubicka-Bączyk, Pierzchała, Machowska-Majchrzak, & Skrzypek, 2012)The 
impact of fatigue on employment has also been studied in groups of MS patients. 
Fatigue was defined by MS patients as their main symptom responsible for their 
cutting back on work hours (Arnett et al., 2008). Fatigue may also cause frequent 
absenteeism from work or loss of employment (Łabuz-Roszak et al., 2012). 
In studies comparing fatigue in NMO and MS populations, fatigue seems 
to be lower in NMO patients than in patients with MS, although these findings are 
only significant in the case of psychological fatigue. Although MS patients were 
more fatigued than NMO patients in cognitive, physical, social, and global areas 
of fatigue assessment, these differences were not statistically significant 
(Chanson et al., 2011). Fatigue is an important factor that relates to decreased 
cognitive function in NMO populations (He et al., 2011) Immunosuppressive 
therapy did not have an effect on levels of fatigue, but this may be due to the 
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adverse side effects of drug treatments (Chanson et al., 2011). Both NMO and 
MS patients are more fatigued than healthy populations. In a study that 
compared NMO, depressed, and healthy populations, NMO fatigue scores were 
significantly higher than in the healthy control population. However, NMO 
patients were less fatigued than the depressed population (He et al., 2011)  
The pathogenesis of fatigue in neuroinflammatory disorders remains 
poorly defined. Some studies implicate pro-inflammatory cytokines such as 
interferon-γ and tumor necrosis factor-α in the development of fatigue in MS 
(Induruwa et al., 2012). An increase in cytokine production is also demonstrated 
in NMO. Although this pattern differs from the one present in MS, cytokines are 
thought to have a role in the development of fatigue in NMO as well (Chanson et 
al., 2011). Additional studies attribute fatigue to deep grey matter pathology, 
cortical atrophy, and axonal damage in the central nervous system (Induruwa et 
al., 2012). Sleep disturbances and side effects of medication are also suggested 
to precipitate fatigue in MS patients (Ghajarzadeh, Jalilian, Eskandari, Ali 
Sahraian, & Reza Azimi, 2012).  
We found no study assessing fatigue in patients with idiopathic transverse 
myelitis. 
Pain 
Another common psychological symptom shared in neuroinflammatory 
disorders is pain. Pain is defined as an unpleasant sensory experience most 
often attributed to tissue damage. There are many types of pain, but the four 
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categories of pain in MS patients are as follows: continuous central neuropathic 
pain, intermittent central neuropathic pain, musculoskeletal pain, and mixed 
neuropathic and non-neuropathic pain (Solaro, Trabucco, & Uccelli, 2013). The 
most common types of pain reported in MS patients are dysthetic leg pain, 
chronic back pain, and leg spasms (Hadjimichael, Kerns, Rizzo, Cutter, & 
Vollmer, 2007).  Pain in MS generally increases with severity of disease (Truini et 
al., 2012). 
Studies on the prevalence of pain in MS patients have used a variety of 
methodologies, with results ranging from 29 to 86% of MS patients reporting pain 
(Solaro et al., 2013). Other studies have attempted to narrow this range and have 
estimated pain in about 50% of MS patients. One-third of MS patients report pain 
as one of their worst symptoms (Arnett et al., 2008; Solaro et al., 2013). 
Pain medications comprise 30% of all drug treatments utilized by MS 
patients (Solaro et al., 2013). Tricyclic antidepressants, antiepileptics, 
intrathecally administered baclofen, opioid analgesics, and cannabinoids have all 
been described for treatment of pain in MS (Solaro et al., 2013). One study found 
that participants with MS used nine treatments on average to manage their pain, 
with greater pain intensity associated with more current treatments utilized 
(Alschuler, Jensen, & Ehde, 2012). However, low satisfaction with pain 
management is typically reported by MS patients (Solaro et al., 2013). 
Other studies on populations of individuals with MS have focused on the 
comorbidity of pain and depression. Pain has a negative association with health-
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related quality of life (Kanamori et al., 2011). One study found over half of 
individuals with MS and pain are clinically depressed. These results are 
significant, as only a third of MS patients not experiencing pain scored above the 
clinical cutoff for depression (Hadjimichael et al., 2007).  
A 2011 study conducted in Japan using the Brief Pain Inventory (BPI) 
determined that pain is more common and more severe in NMO than in MS. 
They found that 83.8% of NMO patients compared to 47.1% of MS patients were 
currently experiencing pain. In addition, the Pain Severity Index score and pain-
related interference in daily life scores were higher in participants with NMO than 
MS. Trunk and bilateral leg pain extending throughout the limbs were also more 
prevalent in NMO patients, whereas MS pain seemed to be concentrated in distal 
regions of limbs (Kanamori et al., 2011). Another study comparing NMO and MS 
populations confirmed these results, noting that “current pain in NMO was twice 
as prevalent and 3 times more severe” compared with a random sample of MS 
patients (Qian et al., 2012). In addition, NMO patients used four times the 
amount of pain medications as MS patients. This polypharmacy did not result in 
effective management of pain, and instead resulted in apparent side effects from 
pain medications such as cognitive dysfunction and fatigue (Qian et al., 2012).  
Analysis of spinal cord lesions in NMO and MS and their effects on pain 
showed that the number of involved spinal cord levels did not predict the 
experience of pain. Spinal lesions in NMO typically involve the central gray 
matter, whereas most MS spinal cord lesions are localized in the posterior and 
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lateral white matter. This may have an influence on the prevalence of pain in 
NMO, as central gray matter has a role the inhibition of pain (Qian et al., 2012). 
Very limited data exists on idiopathic TM patients and their experiences 
with pain. Pain is a common symptom of a TM event. However, studies have not 
longitudinally assessed the residual pain from a remote TM event. Back pain is 
listed as a factor contributing to poor prognosis after a transverse myelitis event 
(Awad & Stüve, 2011; Gajofatto et al., 2010; West et al., 2012). 
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SPECIFIC AIMS 
Decades of research have been dedicated to understanding the physical 
and psychological burden of MS. This data has provided the medical field with 
strong evidence suggesting MS patients are on average, more disabled, fatigued, 
depressed, and pain-ridden than healthy populations. However, because many 
provider visits are dedicated to assessment and treatment of neurological 
disease, many psychological symptoms still go unrecognized and untreated. 
There are relatively few studies on these psychological variables in NMO, and 
almost no studies conducted on populations of TM patients.  
We have constructed this study to compare the levels of disability and 
prevalence of depression, fatigue, and pain across the three most common CNS 
autoimmune inflammatory disorders. Using MS as a comparator group, we hope 
to achieve some insight on how quality of life differs among MS, TM and NMO. 
We also aimed to determine relationships between disability and psychological 
variables. It is difficult to determine a cause-and-effect relationship between 
neurological and psychological conditions in diseases such as NMO, TM, and 
MS. Instead, we set out like to assess the correlations between disability and 
depression, fatigue, and pain. Importantly, we think this study will encourage 
awareness of psychological symptoms and mental health issues plaguing NMO, 
TM, and MS patients. 
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METHODS 
PARTICIPANTS 
All participants recruited in this study were previously seen by providers in 
the Neurology Department at the Johns Hopkins Hospital in Baltimore, MD. 
NMO, TM, and MS patients were selected from provider databases constructed 
during previous research studies. Potential NMO participants were selected 
based on fulfillment of the Wingerchuk 2006 NMO diagnostic criteria and NMO-
IgG seropositivity. Seronegative NMO patients were eliminated from 
consideration to maintain a homogenous population group. We chose potential 
TM participants based on diagnostic criteria for idiopathic transverse myelitis, 
including history or evidence of inflammation in one focal area of the spinal cord 
without recurrence or symptomatic involvement of the brain by history or MRI. 
TM patients were screened to include only those patients who held a diagnosis of 
idiopathic TM 3 or more years past their time of initial symptoms. This measure 
was taken to limit the possibility of including a newly diagnosed TM patient who 
in actuality had the first attack of a recurrent, chronic disorder such as NMO or 
MS. MS participants were selected following a clinically definite diagnosis of MS 
made at the Johns Hopkins MS Center based on two clinical lesions separated in 
time and space and supportive paraclinical data such as a typical MS brain MRI 
or presence of oligoclonal bands in the spinal fluid. A total of 234 (51 NMO, 81 
TM, and 102 MS) patients were contacted by mail regarding participation in this 
survey study. In all, we received completed survey responses from 15 NMO, 12 
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TM, and 23 MS patients. In addition, two TM participants completed a portion of 
the requested surveys. 
PROTOCOL 
We obtained approval for this study from the Institutional Review Board at 
the Johns Hopkins University (NA_00078737). Our study used a password-
protected web-based survey at http://www.nmoresearch.org, which was created 
using the MachForm application developed by Appnitro Software 
(http://www.appnitro.com). 
The recruitment letter mailed to participants (Appendix A) outlined the 
study goals and instructed participants to log onto our website and complete four 
surveys assessing depression, fatigue, pain, and disability. They could save their 
progress and complete these surveys on their own time. We used the Beck 
Depression Inventory (BDI) to assess depression, the Fatigue Severity Scale 
(FSS) to assess fatigue, the Brief Pain Inventory (BPI) to assess pain, and the 
patient-administered Expanded Disability Status Scale (EDSS) score. On each 
survey, the participant entered a unique identification number provided in their 
recruitment letter, which was used to cross reference the subject’s demographic 
data and medical information. Completion of the survey served as the subject’s 
consent to participate in this study. All answers to the survey questions were 
stored in an online password-protected database only accessible to the study 
team members. Additionally, we used existing provider databases to gather 
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personal medical information on each participant’s race, sex, current age, age of 
onset of NMO/TM/MS, and duration since first symptoms of neurological disease. 
In the rare case when a participant wished to participate in this research 
study but did not have access to a computer and/or Internet, we made special 
accommodations. For example, one NMO participant completed the surveys in 
person at the Johns Hopkins NMO Clinic, and one TM participant had the 
surveys administered over the phone by a study team member.  
 
MEASURES USED  
Expanded Disability Status Scale (EDSS) 
The Expanded Disability Status Scale (Kurtzke, 1983) is the most 
commonly used clinical measure of disability in MS patients. Typically, a skilled 
practitioner must complete an EDSS evaluation in a clinical setting, but our 
subjects were not readily available in the Maryland area for a physical 
examination. Our solution was to use Bowen et al.’s self-administered EDSS 
survey developed for use in MS patients (Bowen et al., 2001). 
For our study, we adapted the Bowen study’s self-administered Expanded 
Disability Status Scale (Bowen et al., 2001) for use in NMO and TM. We created 
a collapsed version of this survey and chose to focus on the Pyramidal, 
Cerebellar, Brain Stem, Bowel and Bladder, and Visual FS categories because 
these categories are easily assessed in an online survey format. We eliminated 
the Sensory, Cerebral, and Other FS scores to minimize effort that was not 
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clinically relevant to the entire study population. Our patient-administered 
Expanded Disability Status Scale also modified answer options on the Visual FS, 
as the original survey options were not easily translated to an online format. 
Although our patient-administered EDSS is not comprehensive, the scores can 
be effectively compared between sample groups and correlated with the other 
outcome measures. A copy of the modified patient-administered EDSS survey is 
provided is Appendix B. 
Beck Depression Inventory (BDI) 
The Beck Depression Inventory is a 21-item self-report questionnaire that 
assesses the presence and severity of depressive symptomatology. Beck et al. 
developed this questionnaire to address each separate symptom-attitude 
category (e.g., mood, sense of failure, lack of satisfaction, etc.) (Beck, Ward, 
Mendelson, Mock, & Erbaugh, 1961). A series of four statements under each 
item is associated with a 4-point severity scale ranging from 0 to 3. Individuals 
are asked to choose the statement under each item that best describes how they 
have felt over the past two weeks. The ratings for each item are summed to 
produce a composite BDI score reflecting the individual’s depression status. 
There are four categories of depression an individual may fall under based on 
their BDI score: minimal (0-13), mild (14-19), moderate (20-28), or severe (29-63) 
depression. The BDI is used in both clinical and research settings, and is among 
the most commonly used self-reporting survey tools for assessing depression. 
Over the years, it has demonstrated excellent validity, internal consistency, and 
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test-retest reliability (Arnarson, Ólason, Smári, & SigurÐsson, 2008). The BDI is 
often utilized for clinical and research purposes in MS populations (Zephir et al., 
2003), a reason we have chosen to use this measure in our study. 
The original BDI has been revised several times to reflect the changing 
DSM-IV criteria for depression (Arnau, Meagher, Norris, & Bramson, 2001). The 
most recent version is the Beck Depression Inventory Second Edition (BDI-II). 
We have chosen to use the BDI-II as a screening tool to assess depressive 
symptomatology in our samples of NMO, TM, and MS patients. A copy of the 
online BDI survey is provided in Appendix C. 
Fatigue Severity Scale (FSS) 
The Fatigue Severity Scale was developed to evaluate fatigue in a variety 
of chronic diseases. This scale has demonstrated a high test-retest consistency 
and appropriate correlation with similar scales (Induruwa et al., 2012). In this 
survey, patients are asked to read a series of nine statements addressing their 
symptoms of fatigue over the past week, and choose a number between 1 and 7 
that indicates their agreement with the statement. A low value (e.g., 1) indicates 
strong disagreement with the statement, whereas a high value (e.g., 7) indicates 
strong agreement with the statement. Each patient’s answers are summed to 
provide a composite score of their fatigue. A score of greater than or equal to 36 
suggests the individual is experiencing symptoms of significant fatigue. 
This survey has been administered to study fatigue in multiple sclerosis 
(Induruwa et al., 2012; Łabuz-Roszak et al., 2012). FSS scores have shown 
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excellent internal consistency and test-retest reliability in MS populations (Valko, 
Bassetti, Bloch, Held, & Baumann, 2008), and for this reason we have chosen to 
include FSS scores in our study as the outcome measure for fatigue. A copy of 
the online FSS survey is provided in Appendix D. 
Brief Pain Inventory (BPI) 
Cleeland developed the Brief Pain Inventory in 1991 as a tool to measure 
pain in cancer patients (Cleeland et al., 1994). This screening tool was 
developed following increased awareness of poor pain management in cancer 
patients, especially in the late stages of disease. Since its creation, the BPI has 
been used in over 400 studies worldwide. The BPI has been expanded from its 
original use in cancer populations, and is now used to assess pain in a variety of 
illnesses that produce chronic pain. 
The BPI has several question formats and focuses on severity of pain and 
how pain has interfered with an individual’s daily activities over the past 24 hours. 
In the short form BPI, the first item asks patients whether or not they have 
experienced pain outside the realm of what is considered “normal” pain (e.g., 
minor headaches, sprains, etc.) that day. The next item asks patients to diagram 
where their pain is located on a chart of the human body. Since this question 
could not be efficiently translated to an online survey format, we used a checklist 
option in which patients selected areas where they felt pain. Next on the short 
form survey is a set of four pain severity questions that ask patients to rate their 
pain on a scale of 0 (no pain) to 10 (worst pain you can imagine). The four 
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questions focus on 1) the worst pain patients experienced in the past 24 hours, 
2) the least amount of pain patients experienced in the past 24 hours, 3) the 
amount of pain patients experience on the average, and 4) the amount of pain 
patients are currently experiencing while completing the survey. We calculated 
the Pain Severity Index score by averaging the 4 pain severity scores. The final 
seven questions on the BPI comprise the section on pain interference. These 
questions center on the impact of patients’ pain in various aspects of their lives: 
general activity, mood, walking ability, normal work, relations with other people, 
sleep, and enjoyment of life. These questions are also assessed on a scale from 
0 (pain does not interfere in this category) to 10 (pain completely interferes). 
These individual interference scores were averaged to determine a mean pain 
interference score for each patient. 
Several studies have used the BPI to assess pain in populations of 
multiple sclerosis and neuromyelitis optica patients (Kanamori et al., 2011). 
There is a long form BPI as well as a short form version of the BPI. The long form 
is typically used for baseline measurements in clinical trials, while the short form 
is used for clinical research. We have chosen to use the short form Brief Pain 
Inventory in our web study, and a copy of the online BPI survey is available in 
Appendix E. 
STATISTICAL ANALYSES 
 Current ages, ages at onset, and duration of disease means were 
calculated for each disease group. We tested these group means using a one-
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way analysis of variance (ANOVA). Means and medians were calculated for each 
of the outcome measure scores (i.e. EDSS, BDI, FSS, BPI). The outcome 
measure data did not fit a Gaussian distribution. Therefore, NMO, TM, and MS 
patients were compared based on these measures using the non-parametric 
Kruskal-Wallis one-way ANOVA. We also conducted correlation analyses on 
demographic and outcome variables within each disease group, and used a 
linear regression model to illustrate the relationship between EDSS and BDI 
scores. ANOVA and correlation statistics were considered significant at a p-value 
< 0.05. 
 Insufficient data points precluded a chi-squared analysis on the 
categorical variables (i.e. sex, race, levels of depression). 
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RESULTS 
SAMPLE GROUPS 
 We collected demographic data from our groups of NMO, TM, and MS 
patients to determine whether the distribution of race, sex, age, and duration of 
disease between these groups was similar enough to warrant comparison on 
other measures. Table 2 provides information on the distribution of sex and race 
among the three samples.   
Table 2. Participant demographics- sex and race.  
 Demographic data from 15 NMO, 14 TM, and 23 MS patients.  
 Number of participants in each category are listed, followed by percentage  
 distributions. 
 
The NMO and MS participant groups were predominantly female, 100% 
and 50% respectively, while the TM group had an equal distribution of males to 
females. The TM group was composed entirely of white participants, while the 
  37 
NMO and MS groups included participants of other races. The NMO group had 
the highest percentage of non-white participants. 
A longer duration of disease may indicate further progression of a chronic 
neurological disease, especially in the case of progressive MS. Progressive 
disease is always marked with increased disability. Current age of participants 
may also have an impact on the psychological variables we are studying. A 
comparison of these ages and periods of time are located in Table 3. The MS 
patients had the lowest current ages and ages at onset, but had the highest 
duration of disease. Values of current age and age at onset were more similar 
between NMO and TM groups, but NMO patients tended to have a longer 
duration of disease. This demographic data exhibits high variability within each 
sample group, so histograms of these variables were constructed. Histograms for 
each age/time variable reflected a widely spread distribution in each disease 
group. 
 
Table 3. Participant demographics- current age, age at onset, and duration 
of disease. Means ± standard deviations of the mean (SD) are listed by disease 
group. All values are in years. 
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For the current age and age at onset histograms, the MS distribution spanned 
the lowest values, while the NMO distribution spanned the highest values. The 
duration of disease histogram showed lower distribution values for TM, and 
higher values in MS. However, testing by ANOVA determined there were no 
significant differences in age or disease duration among any of these groups. 
 
OUTCOME MEASURES 
After participants completed the online surveys, we analyzed the data to 
determine whether significant differences existed between EDSS, BDI, FSS, and 
BPI score means in each disease group. In order to account for disability as 
factor in depression, fatigue and pain, BDI/EDSS and FSS/EDSS ratios were 
also calculated and compared for the NMO, TM, and MS groups. The medians, 
means, and significance between group means are listed for each test in Table 4. 
None of the ANOVA calculations for each outcome measure were statistically 
significant, suggesting there are no statistical differences among NMO, TM, and 
MS patients on scales of disability, depression, fatigue, and pain. However, a 
claim for a strong trend of the BDI/EDSS and FSS/EDSS ratios emerged, as they 
nearly approach a p-value of 0.05 (p < 0.082 and p < 0.051, respectively). 
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Table 4. Outcome measure medians, means, and ANOVA p-values. The 
medians, means ± SD, and significance of p-values by ANOVA are listed for 
each outcome measure: EDSS, BDI, FSS, BPI Index, BDI/EDSS Ratio, and 
FSS/EDSS Ratio. 
 
 
EDSS 
 The means of EDSS scores between NMO, TM, and MS patients were not 
statistically different among disease groups (Table 4). Because there were 
outliers in each group that may have skewed group means, a box-whisker plot 
was constructed (Figure 1) to compare the data using the medians of each 
group. The median EDSS scores in each group were 5.5 (NMO), 5.75 (TM), and 
4.5 (MS). Although it is not statistically significant, a trend is observed which 
suggests that NMO and TM populations scored higher on measures of disability 
than MS populations. 
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Figure 1. Box-and-whisker plot of EDSS scores for NMO, TM, and MS 
groups. Medians are 5.5, 5.75, and 4.5 for NMO, TM, and MS, respectively. 
Whiskers extend from minimum to maximum data points. 
  
BDI 
 Mean BDI scores from NMO, TM, MS patients were also not statistically 
significant according to ANOVA. However, a box-and-whisker plot provides a 
way of looking at the data qualitatively (Figure 2). The median BDI scores in each 
group were 8 (NMO), 16.5 (TM), and 18 (MS). This plot suggests that the MS 
and TM patients in our sample scored higher than NMO patients on measures of 
depression. It is worth noting that the NMO interquartile range (data between the 
25th and 75th percentiles) comprises much lower BDI scores and has a smaller 
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sample variance than the IQRs for the MS and TM groups. The NMO group had 
several outliers with BDI scores much higher than the middle 50% of the group 
data, which resulted in a higher mean (12) than the median (8) in NMO. The 
NMO group mean (12) was more similar to the TM and MS means (19 and 16.4, 
respectively), providing some insight on why ANOVA found no significant group 
BDI differences.  
  
Figure 2. Box-and-whisker plot of BDI scores for NMO, TM, and MS groups. 
Group medians are 8 (NMO), 16.5 (TM), and 18 (MS). Whiskers extend from 
minimum to maximum data points. 
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 Because NMO patients seemed to be less depressed yet more disabled 
than MS patients, we looked at how the BDI scores of patients compared to their 
EDSS scores. Ratios of BDI scores to EDSS scores were calculated for each 
disease group. ANOVA revealed a p-value of 0.082, approaching but not 
reaching the level required for significance, but highlighting the trend that NMO 
patients were less depressed despite living with more disability.  
  
Figure 3. Box-and-whisker plot of BDI/EDSS Ratios for NMO, TM, and MS 
groups. Group medians are 1.75 (NMO), 2.79 (TM), and 3.33 (MS). Whiskers 
extend from minimum to maximum data points. 
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The data for BDI/EDSS ratios in each disease group is presented in 
Figure 3. TM and MS BDI/EDSS ratios were higher and more variable than NMO 
BDI/EDSS values. The low variance in NMO patient BDI/EDSS scores suggests 
they routinely scored lower on measures of depression while scoring higher on 
measures of disability.  
 Beck Depression Inventory Scores are divided into four subcategories that 
classify the depression status of an individual: minimal depression (0-13), mild 
depression (14-19), moderate depression (20-28), or severe depression (29-63). 
There was not enough data to conduct a chi-squared analysis on this measure, 
but rough comparisons can be made based on percentages of participants in 
each subcategory. Figure 4 shows that the overwhelming majority (73%) of NMO 
participants had minimal or no signs of depression, while over half of the TM and 
MS participants exhibited mild to severe depressive symptomatology. 
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Figure 4. Severity of depression in NMO, TM, and MS patients. Participants 
were grouped into depression severity levels according to BDI scores: minimal 
depression (0-13), mild depression (14-19), moderate depression (20-28), or 
severe depression (29-63). Depression severity levels were color-coded: minimal 
(blue), mild (red), moderate (green), or severe (purple). 
 
 
FSS 
 ANOVA revealed that Fatigue Severity Score means were not statistically 
different between NMO, TM, and MS groups (Table 4). A box-and-whisker plot 
(Figure 5) shows that median FSS scores for the NMO and TM groups (39 and 
41, respectively) were lower than median FSS scores in MS (49). However, the 
TM group has a high distribution of scores above the median, suggesting TM 
patients may score more similarly to MS patients on measures of fatigue. 
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Figure 5. Box-and-whisker plot of FSS Scores for NMO, TM, and MS groups. 
Group medians are 39 (NMO), 41 (TM), and 49 (MS). Whiskers extend from 
minimum to maximum data points. 
 
 We calculated the FSS/EDSS ratios for the disease groups, and ran an 
ANOVA to test the differences among group means. The p-value was nearly 
significant (0.051), suggesting there may be a difference between FSS/EDSS 
ratios in NMO, TM, and MS. We also constructed a box-and-whisker plot to 
display the data (Figure 6). Again, the NMO group displayed the least amount of 
variance in the ratio measure. The MS group contained the highest FSS/EDSS 
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ratio, signifying higher fatigue scores, lower disability levels, or some combination 
of the two factors.  
  
Figure 6. Box-and-whisker plot of FSS/EDSS Ratios for NMO, TM, and MS 
groups. Group medians are 7.5 (NMO), 8.76 (TM), and 10.25 (MS). Whiskers 
extend from minimum to maximum data points. 
 
 An FSS score ≥ 36 suggests an individual is suffering from symptoms of 
significant fatigue. Although we compared FSS scores on a continuous scale, it is 
necessary to grasp the percentage of participants per disease group who scored 
above 36 on the FSS, and thus are truly fatigued. Figure 7 illustrates the 
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percentages of NMO, TM, and MS participants with or without significant fatigue. 
The TM group contained the highest percentage of fatigued participants (77%), 
compared with 74% of MS participants and only 60% of NMO participants. 
 
 
Figure 7. Percentages of NMO, TM, and MS participants with and without 
significant fatigue. Participants were defined as having symptoms of significant 
fatigue with an FSS score ≥ 36 NMO percentages are shown in blue, TM 
percentages are shown in red, and MS percentages are shown in green. 
 
BPI 
 The Brief Pain Inventory is composed of questions addressing pain 
severity and pain interference in daily activities. The first question asks 
participants whether or not they have experienced abnormal pain that day. The 
question format is yes/no, making it possible to compare percentages of 
participants with and without current pain. Figure 8 depicts participants’ answers 
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to this question. 80% of NMO patients, 67% of TM patients, and 65% of MS 
patients reported experiencing pain the day they took the BPI. 
 
 
 
Figure 8. Percentages of NMO, TM, and MS participants currently 
experiencing pain. Participants were asked on the BPI to indicate whether they 
had experienced pain that day. NMO percentages are shown in blue, TM 
percentages are shown in red, and MS percentages are shown in green. 
 
 The next four questions on the BPI address pain severity. Participants are 
asked to rate their pain from 0 (least) to 10 (worst) based on: 1) the worst pain 
they experienced in the past 24 hours, 2) the least pain experienced in the past 
24 hours, 3) their average amount of pain, and 4) their current pain level. These 
four scores are averaged to produce the BPI Pain Severity Index score. The BPI 
Index score was plotted for each disease group in Figure 9. NMO and TM 
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patients appear to score higher on the BPI Index than MS patients, according to 
the group medians. However, ANOVA did not reveal any significant differences 
between means of the groups (Table 4). 
  
Figure 9. Box-and-whisker plot of BPI Pain Severity Index scores for NMO, 
TM, and MS groups. Participants’ scores for worst and least pain in the past 24 
hours, average pain, and current pain were averaged to obtain the BPI Index 
score. Group medians are 5 (NMO), 4.75 (TM), and 2.75 (MS). Whiskers extend 
from minimum to maximum data points. 
 
 The final set of questions on the BPI address the interference of pain in 
aspects of participants’ daily lives; specifically, their general activity, mood, 
walking ability, normal work, relations with other people, sleep, and enjoyment of 
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life. Participants rate the interference of pain on a scale of 0 (pain does not 
interfere) to 10 (interferes completely), and the seven questions are averaged to 
produce the BPI Pain Interference score. Figure 10 depicts the distribution of BPI 
Interference scores between NMO, TM, and MS groups. All three groups have 
very similar medians, but the interquartile range of the TM group indicates a wide 
spread of the data over the 0 to 10 scale.  
  
Figure 10. Box-and-whisker plot of BPI Pain Interference scores for NMO, 
TM, and MS groups. The seven BPI questions regarding pain interference were 
averaged to produce a BPI Interference score for each participant. Group 
medians are 2.86 (NMO), 3 (TM), and 3.57 (MS). Whiskers extend from minimum 
to maximum data points. 
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CORRELATIONS 
 In the final component of our analysis, we aimed to assess the 
relationships among each of our variables. The relationship between disability 
and depression is of particular interest to our group, and a scatter plot of patient 
scores for the two measures are shown in Figure 11. We used regression 
analysis to determine the relationship between EDSS scores and BDI scores for 
each disease group. A linear relationship between these two variables was only 
observed in the MS group. NMO patients exhibited rising depression scores with 
increased disability level until an EDSS score of about 6.5, after which 
depression scores decreased with higher EDSS scores. TM patients’ BDI and 
EDSS scores seemed to rise together only briefly, becoming negatively 
associated at EDSS values above 4.  
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Figure 11. Linear regression model of EDSS vs. BDI scores by disease 
group. Data points were plotted, and regression analysis determined trends in 
NMO (black), TM (red), and MS (green). The MS group showed the only linear 
trend. 
 
We conducted linear correlation tests to determine the Pearson Product 
Moment correlation coefficients (r) between variables (Table 5). The 
demographic and outcome variables we chose to compare were current age, age 
at onset, duration of disease, EDSS score, BDI score, FSS score, BPI Index 
score, and BPI Interference score.  
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 Only the BDI vs. BPI Interference and FSS vs. BPI Interference correlation 
analyses were significant across all three groups. The BDI vs. BPI Interference 
correlation analysis produced significant r-values of +0.66 (NMO), +0.71 (TM), 
and +0.59, indicating a positive linear relationship between BDI scores and BPI 
Index scores in NMO, TM, and MS. The FSS vs. BPI Interference analysis 
yielded significant positive r-values of +0.66 (NMO), +0.68 (TM), and +0.63 (MS). 
 Additional analyses found significant correlations between 
demographic/outcome variables in two disease groups. EDSS vs. BPI Index and 
EDSS vs. BPI Interference analyses showed positive correlations in NMO and 
MS, but not in TM. BDI vs. BPI Index and FSS vs. BPI Index correlation analyses 
demonstrated a positive association between these variables in the TM and MS 
groups, but not in the NMO group.  
 Correlation analyses revealed associations between variables in only one 
disease group. Positive correlations in NMO existed in the EDSS vs. Current Age 
and EDSS vs. Age at Onset relationships. Positive correlations in the MS groups 
were found in EDSS vs. Duration of Disease, EDSS vs. BDI, EDSS vs. FSS, and 
BDI vs. FSS correlation analyses. 
 The only negative relationship discovered through correlation analysis 
occurred in the MS group. MS participant Age at Onset was negatively 
associated with Duration of Disease (r = -0.49).  
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Table 5. Correlations between outcome variables, demographic variables, 
and outcome vs. demographic variables. Pearson Product Moment correlation 
coefficients (r) and p-value (p) significance are listed for NMO, TM, and MS. 
Bolded values are significant (p < 0.05). 
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DISCUSSION 
Demographic Data 
In order to draw any meaningful conclusions from the data, we must first 
address the appropriateness of our sample subjects. The NMO and MS subjects 
who participated in our survey study were composed predominantly of women as 
expected, as there is a higher likelihood of women developing these autoimmune 
disorders and therefore a higher ratio of women to men who have MS or NMO. 
The TM group was composed of exactly 50% males and 50% females, which is 
also in accordance with epidemiological data that TM does not preferentially 
affect one gender over another. Therefore, while our sample was skewed in 
terms of participant sex, it was consistent with the ratio found in these disease 
populations. 
 In terms of race, our groups, while somewhat different from one another, 
reflect the proportions present in clinical data. Non-white populations, especially 
of African descent, are overrepresented in NMO cases. Our NMO sample reflects 
this expected ratio. On the other hand, MS patients are predominantly white. 
Once again, our sample was representative as 83% of our MS participants were 
white. One hundred percent of our TM patients were white, reflecting recent data 
suggesting monophasic inflammatory spinal cord diseases like TM are more 
common in whites while recurrent diseases like NMO are common among non-
whites. Therefore, while our sample groups do not contain equal proportions of 
race and gender, our sample contains demographic data representative of what 
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might be expected in a clinical setting. Patient ages and durations of disease 
were also not statistically different across NMO, TM, and MS sample groups.  
  
Outcome Variables 
 In this section, we will address the categories of disability, depression, 
fatigue, and pain in each of the disease groups. None of these measures were 
strictly statistically significant as defined as a p-value less than 0.05 by ANOVA. 
However, because the data was not normally distributed, other ways of observing 
and interpreting the data were utilized. We used box-and-whisker plots, outcome 
variable ratios, and categorical grouping to better understand the implications of 
our data. 
 We observed trends suggesting NMO and TM patients are typically more 
disabled than MS patients. In addition, NMO patients appeared to be less 
depressed than TM and MS patients. Almost three out of every four NMO 
patients were categorized as having little to no depressive symptoms. Only about 
one of four NMO patients compared to over half of TM and MS patients exhibited 
mild to severe depressive symptomatology. This was an interesting result, as we 
had originally hypothesized that patients with higher levels of disability would in 
turn be more depressed. A BDI/EDSS ratio analysis between groups suggested 
our sample of NMO patients was more disabled, yet less depressed (low 
BDI/EDSS ratio) than MS patients, who were less disabled but more depressed 
(high BDI/EDSS ratio). TM patients scored high on measures of both disability 
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and depression, resulting in a group median BDI/EDSS ratio falling between the 
NMO and MS BDI/EDSS ratio medians.  
We had originally assumed that individuals with higher levels of disability 
might also exhibit higher levels of depression. This hypothesis was based on the 
idea that disability alters an individual’s ability to carry out daily activities, which 
may in turn cause feelings of frustration, helplessness, and despair. However, 
NMO patients exhibited the lowest depression scores despite being more 
disabled than MS patients. Therefore, variables other than disability must play a 
role in mediating the effects of depression on these patient populations. For 
example, the biological location of lesions may play a role in the onset of 
depression. Recent research has indicated that MS patients with lesions in the 
brain are more depressed than patients with lesions localized to the spinal cord 
(Siegert & Abernethy, 2005). However, the biological location of lesions does not 
explain why depression in TM patients more closely mirrors levels in MS, as TM 
lesions are localized to the spinal cord. One theory on why TM patients exhibit 
high levels of depression may focus on patients’ perception of control over their 
own health. NMO and MS are both chronic, recurrent diseases, while 
monophasic idiopathic TM is a one-time event. MS and NMO are actively treated 
with immunosuppressive therapy throughout the course of a patient’s life. On the 
other hand, an idiopathic TM event is only treated throughout the episode. Once 
a TM event has ceased, the patient is often left with residual disability and pain 
that would not be alleviated by additional immunosuppressive therapy, and 
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treatment is therefore limited. TM patients may view their disease as a life-
changing event that remains out of their control, both in its initiation and 
aftereffects. They may view their residual disability as concrete with limited hope 
for improvement, and this may result in feelings of hopelessness and depression.  
 We observed a trend suggesting MS and TM patients are also more 
fatigued than NMO patients. 77% of TM and 74% of MS patients exceeded the 
FSS score cutoff for determining significant fatigue, while only 60% of NMO 
patients did. An FSS/EDSS ratio analysis between groups revealed this measure 
was very close to being significantly different across disease groups. NMO 
patients had the lowest FSS/EDSS ratios, signifying lower fatigue scores despite 
higher disability levels. MS patients had the highest FSS/EDSS ratios, 
suggesting they may be more fatigued even with lower levels of disability. Finally, 
TM patients had intermediate FSS/EDSS ratios as a result of higher levels of 
both fatigue and disability.  
We had hypothesized that fatigue may be positively correlated with 
disability across disease groups, but our data suggests NMO patients have less 
symptoms of fatigue despite more disability than MS patients. This finding may 
have some biological basis, as the anatomical target of each disease may cause 
some patients to be more susceptible to significant fatigue. Previous research on 
fatigue in MS has postulated links between symptoms of fatigue and location of 
lesions in the brain. NMO and TM, on the other hand, have most of the disease 
burden localized outside the brain. We must also take into account that fatigue is 
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a multifaceted concept, with both physical and psychological symptoms. There 
are preliminary reports that MS patients have higher levels of cognitive deficits 
than their NMO counterparts, likely due to the lesion load in the brain. Problems 
with cognition may contribute to the prevalence of fatigue in MS patients. We 
have not distinguished between these types of symptoms in our study. However, 
this theory does not explain the high percentage of TM patients with symptoms of 
significant fatigue. It has been suggested that fatigue in TM may be related to the 
increased depression observed in this patient population. 
 NMO and TM patients reported higher severity of pain as compared to MS 
patients. 80% of NMO patients reporting experiencing pain on the day they took 
the BPI, compared with 67% and 65% of TM and MS patients, respectively. The 
interference of pain in patients’ daily lives did not significantly differ across 
disease groups but MS patients had slightly higher interference scores.  
Chronic pain has been attributed to the development or worsening of 
depressive symptoms in many populations. Spinal cord disease of any etiology 
often produces neuropathic pain of a higher caliber, and this is evident in our 
study sample. However, pain is not strictly limited to presence and severity, as it 
has a distinct psychological component. An individual’s ability to cope with pain 
can potentially have a significant impact on how pain interferes in their daily life, 
and in their likelihood of developing depression. Although NMO and TM patients 
exhibited higher BPI Pain Severity Index score, the highest BPI interference 
scores were present in MS patients. Therefore, although pain was more severe 
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in NMO and TM patients, these patients likely had better coping skills to 
decrease the likelihood of pain having a significant impact on their daily lives.  
 
Correlations between Variables 
 One of the main objectives of our study was to determine the relationships 
between disability and other psychological factors in NMO, TM, and MS. 
Because two TM patients did not complete all four surveys, we discarded their 
demographic and outcome variable data for the correlation analysis. The 
correlation and regression analysis of EDSS vs. BDI score in each group yielded 
both expected and unexpected results. Disability and depression scores 
exhibited a strong, positive correlation in MS, as we had predicted. However, this 
relationship in NMO and TM patients was much different. NMO patients exhibited 
a large peak in depression around an EDSS score of 6.5, with patients scoring 
lower on the BDI at both ends of the disability spectrum. TM patients, on the 
other hand, almost exhibited a negative correlation between EDSS and BDI 
scores. This finding is puzzling, but we cannot rule out that it is an artifact of 
sample size. We had 23 MS patients compared to 15 NMO and 12 TM patients in 
this correlation analysis, and the large number of MS data points likely allowed a 
linear correlation to be established. An additional explanation might be that 
depression correlates with duration of disease. As MS is a progressive disease, 
higher disability correlates with longer duration of disease. In contrast, TM and 
NMO patients can develop severe disability early in the disease course.  
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 We also analyzed the relationship of EDSS scores to the other 
psychological outcome variables. There was a positive correlation between 
EDSS score and FSS score in MS, but no other disease group. EDSS vs. BPI 
Index and EDSS vs. BPI Interference r-scores were also significant, with a 
positive correlation in both NMO and MS groups. Our disability measure 
positively correlated with BDI, FSS, BPI Index, and BPI Interference only in the 
MS sample supporting the broader notion that disability in MS is associated with 
clinical depression, pain and fatigue. However, increased disability is not 
associated with higher levels of depression, fatigue, and pain in NMO and TM. 
Although a clear explanation for this finding has not been established, possible 
reasons may include disease differences in biology, prognoses, coping skills, 
and/or perceived control over events related to NMO, TM, or MS. 
 Since our prediction on the relationship between disability and decreased 
psychological well-being did not prove true across all three groups, we conducted 
additional correlational analyses to determine if any demographic or outcome 
variables were universally correlated across all three groups. The only two 
significant relationships we discovered were in BDI vs. BPI Interference scores 
and FSS vs. BPI Interference scores suggesting that pain can lead to depression 
and pain in any disease. Both of these were strongly positive correlations. This 
finding is interesting and expected. Past literature has emphasized the positive 
relationship between depression and fatigue. The BPI Interference score 
captures patients’ perception of how pain interferes in their daily activities. 
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Therefore, our correlation studies suggest that when depressed and/or fatigued 
participants experience pain, they feel pain has a greater negative impact on 
their daily activities than participants who are not depressed or fatigued. 
Relationships between psychological variables are complex, and we would 
expect the BPI Interference score to be mediated by not only pain severity, but 
also how a patient copes with their pain. 
 The origin of psychological issues in NMO, TM, and MS patients remains 
vague. NMO and TM attack the spinal cord, whereas MS lesions include targets 
in the brain. Spinal cord disease is typically more disabling and painful than 
disease in the brain. However, MS patients are likely more depressed and 
fatigued than NMO patients. This precipitates questions of whether MS patients 
are more depressed and fatigued due to the biological location of neurological 
disease in the brain, one of the many environmental factors thought to elicit 
depression, or some combination of biological and environmental causes. A 
biological explanation for increased levels of depression in MS would not, 
however, account for the prevalence of depression in TM patients. Almost 
certainly, future research on neurological diseases will attack the complexity of 
these questions. 
 The main limitations of our study rest on sample size. NMO and TM are 
rare diseases, making participant recruitment difficult. We received a 21% 
response rate out of 234 recruited participants, resulting in a total sample of 50 
patients.  
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 An additional study limitation is our restricted accounting for other 
variables that might affect the physical and psychological well-being of patients 
(e.g., current medications, whether they were currently experiencing a relapse, 
history of psychiatric disorders, etc.). Our patient-administered EDSS score only 
included several functional system scores, and a comprehensive survey would 
have yielded more data on patients’ disability levels. Finally, the online format of 
our study, while convenient, may have limited our study participants to those who 
had access to a computer and Internet. 
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